| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Atlantic AllCare is a Deerfield Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Masterson Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marquette General Health System is a Marquette, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blakehurst Retirement Community is a life plan community in the Baltimore area that offers a range of residential options and amenities designed to contribute to residents’ overall happiness and well-being. They specialize in senior living communities ...